Director Amy E. Herr filed a Form 4 with the SEC on November 2, 2026, reporting the acquisition of 2,750 shares of Bio-Techne Corp common stock on October 29, 2026, at a price of $0.

Key Highlights

  • Transaction: Amy E. Herr acquired 2,750 shares of Bio-Techne Corp common stock on October 29, 2026, with a recorded price of $0, coded as an acquisition (A).
  • Post-transaction direct ownership: Following the transaction, Herr directly holds 5,430 shares of common stock.
  • Indirect ownership: An additional 576 shares are held indirectly by a significant other, per the filing.
  • Stock options disclosed: Multiple stock options are reported, both directly and indirectly through a significant other, with exercise prices ranging from $53.60 to $120.46.
  • Restricted stock units: Several RSU tranches are disclosed indirectly held by a significant other, covering a total of 2,239 RSUs with vesting dates spanning 2026 through 2029.
  • Issuer: The filing identifies the issuer as BIO-TECHNE Corp, traded on NASDAQ:TECH.

Amy Herr's October 2026 Acquisition and Beneficial Ownership at Bio-Techne

According to the Form 4 filed on November 2, 2026, Amy E. Herr, a director of BIO-TECHNE Corp (NASDAQ:TECH), reported a transaction dated October 29, 2026, in which she acquired 2,750 shares of Bio-Techne common stock at a price of $0. The filing lists the transaction code as "A" (acquisition). Following this transaction, Herr directly beneficially owns 5,430 shares of common stock. An additional 576 shares are held indirectly through a significant other, the filing states.

The filing also discloses a range of derivative securities held indirectly through a significant other. These include stock options with exercise prices of $66.97 (expiring 08/05/2027, covering 4,472 shares), $120.46 (expiring 08/06/2028, covering 2,076 shares), $94.52 (expiring 08/15/2029, covering 2,104 shares), $84.61 (expiring 08/15/2030, covering 1,084 shares), $74.91 (expiring 08/15/2034, covering 1,468 shares), $72.05 (expiring 02/03/2035, covering 344 shares), and $53.60 (expiring 08/15/2035, covering 2,735 shares). Two additional stock options are held directly: 2,415 shares at $72.05 expiring 02/03/2035, and 3,777 shares at $60.96 expiring 10/30/2035. Several of these options are described as fully vested per the filing's footnotes.

Additionally, the filing reports four tranches of restricted stock units held indirectly through a significant other, totaling 2,239 RSUs, with vesting schedules running from 2026 through 2029. Each restricted stock unit, according to the filing, "represents a contingent right to receive one share of Bio-Techne common stock." The Form 4 was signed by Andrew Nick as attorney-in-fact for Amy E. Herr pursuant to a previously filed power of attorney.

What Was Disclosed

Director Amy E. Herr reported the acquisition of 2,750 Bio-Techne common shares at $0 on October 29, 2026, bringing her direct holdings to 5,430 shares, alongside multiple indirectly held stock options and restricted stock units disclosed through a significant other.